Quarterly ResultMay 14, 2026, 08:07 AM
Keros Therapeutics Q1 Revenue $367K; Net Loss $(23.7M)
AI Summary
Keros Therapeutics reported a net loss of $(23.7) million for Q1 2026, a significant decline from a net income of $148.5 million in Q1 2025. Total revenue plummeted to $367 thousand from $211.2 million year-over-year, primarily due to the absence of large license revenue recognized in the prior year. The company's cash and cash equivalents stood at $281.5 million as of March 31, 2026, down from $287.4 million at the end of 2025. Management believes existing cash will allow operations for at least the next 12 months, but continued viability depends on raising additional capital.
Key Highlights
- Net loss was $(23.7) million in Q1 2026, compared to net income of $148.5 million in Q1 2025.
- Total revenue decreased to $367 thousand in Q1 2026 from $211.2 million in Q1 2025.
- Basic and diluted net loss per share was $(1.21) in Q1 2026, down from $3.66 income per share in Q1 2025.
- Cash and cash equivalents were $281.5 million as of March 31, 2026, a decrease from $287.4 million at December 31, 2025.
- Research and development expenses decreased to $16.1 million in Q1 2026 from $48.7 million in Q1 2025.
- General and administrative expenses were $10.1 million in Q1 2026, slightly down from $10.5 million in Q1 2025.
- The $375.0 million capital return program, including share repurchases, was completed in Q4 2025.
- The stockholder rights plan expired on April 9, 2026.
Price Impact
More from KROS